Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $273.00 at Wedbush

Ascendis Pharma A/S (NASDAQ:ASND) had its price target increased by Wedbush from $240.00 to $273.00 in a research report sent to investors on Thursday, MarketBeat.com reports. Wedbush currently has an outperform rating on the biotechnology company’s stock.

ASND has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Barclays started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 27th. They set an “overweight” rating and a $342.00 target price for the company. Royal Bank Of Canada raised their price target on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Finally, Bank of America lifted their price objective on Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $284.00.

Ascendis Pharma A/S Stock Down 1.5%

Shares of NASDAQ ASND opened at $218.10 on Thursday. Ascendis Pharma A/S has a 12-month low of $124.06 and a 12-month high of $242.00. The firm’s 50-day simple moving average is $214.64 and its 200 day simple moving average is $204.49. The company has a market cap of $13.52 billion, a price-to-earnings ratio of -49.57 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The business had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. On average, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $26,000. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth $36,000. Global Retirement Partners LLC boosted its position in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares in the last quarter. GW&K Investment Management LLC boosted its position in shares of Ascendis Pharma A/S by 75.2% during the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 97 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 83 shares during the period.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Strong revenue / product momentum: Ascendis reported Q4 revenue of $290.3M (above consensus) and highlighted robust YORVIPATH sales and growth momentum on the earnings call. This supports the company’s commercial trajectory. Read More.
• Positive Sentiment: Analyst upgrade / higher price target: Wedbush raised its price target from $240 to $273 and maintained an Outperform rating, implying ~25% upside from current levels and signaling analyst confidence in longer-term upside. Read More.
• Neutral Sentiment: Full earnings disclosure / transcripts available: Multiple transcripts and call highlights (TipRanks, Seeking Alpha, Yahoo) provide detail on guidance, commercialization cadence and pipeline positioning — useful for investors doing deeper due diligence but not immediate catalysts. Read More. • Read More.
• Neutral Sentiment: Short interest data shows no meaningful change (reported as zero in recent filings), so short-position flow does not appear to be a driving factor today. (Data items reported by market trackers.)
• Negative Sentiment: Big EPS miss: Ascendis reported GAAP EPS of ($0.64) vs. consensus $0.13 — a material miss that weighs on near-term sentiment despite revenue strength. Investors often punish earnings misses even when sales are growing. Read More.
• Negative Sentiment: Competitive risk in achondroplasia: Broader sector news (BridgeBio moves) has shifted the competitive landscape for achondroplasia treatments, pressuring peers including Ascendis and BioMarin. That dynamic is a headline-driven negative for the stock. Read More.
• Negative Sentiment: Conflicting coverage on revenue vs. estimates: Some outlets reported the quarter missed revenue expectations despite strong YORVIPATH uptake, adding short-term noise and uncertainty around street estimates. Read More.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.